Vascular endothelial growth factor stimulates rat cholangiocyte proliferation via an autocrine mechanism

…, A Franchitto, P Onori, M Marzioni, S Taffetani, G Fava… - Gastroenterology, 2006 - Elsevier
Background & Aims: Vascular endothelial growth factor (VEGF) is secreted by several
epithelia and modulates cellular functions by autocrine and paracrine mechanisms. The role of …

VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICE‐1 study

…, M Iavarone, P Toniutto, G Fava… - … journal of cancer, 2014 - Wiley Online Library
Although new treatment modalities changed the global approach to hepatocellular
carcinoma (HCC), this disease still represents a medical challenge. Currently, the therapeutic …

cAMP stimulates the secretory and proliferative capacity of the rat intrahepatic biliary epithelium through changes in the PKA/Src/MEK/ERK1/2 pathway

…, D Alvaro, J Venter, R Reichenbach, G Fava… - Journal of …, 2004 - Elsevier
BACKGROUND/AIMS: To evaluate if increased cholangiocyte cAMP levels alone are
sufficient to enhance cholangiocyte proliferation and secretion. METHODS: Normal rats were …

Autocrine/paracrine regulation of the growth of the biliary tree by the neuroendocrine hormone serotonin

…, Y Ueno, T Roskams, JL Phinizy, J Venter, G Fava… - Gastroenterology, 2005 - Elsevier
Background & Aims: The biliary tree is the target of cholangiopathies that are chronic cholestatic
liver diseases characterized by loss of proliferative response and enhanced apoptosis …

γ-aminobutyric acid inhibits cholangiocarcinoma growth by cyclic AMP–dependent regulation of the protein kinase a/extracellular signal-regulated kinase 1/2 pathway

G Fava, L Marucci, S Glaser, H Francis, S De Morrow… - Cancer Research, 2005 - AACR
We studied the effect of the inhibitory neurotransmitter, γ-aminobutyric acid (GABA), in the
regulation of cholangiocarcinoma growth. We determined the in vitro effect of GABA on the …

Leptin enhances cholangiocarcinoma cell growth

G Fava, G Alpini, C Rychlicki, S Saccomanno… - Cancer Research, 2008 - AACR
Cholangiocarcinoma is a strongly aggressive malignancy with a very poor prognosis.
Effective therapeutic strategies are lacking because molecular mechanisms regulating …

[HTML][HTML] Heterogeneity of the intrahepatic biliary epithelium

…, S DeMorrow, G LeSage, G Fava… - World journal of …, 2006 - ncbi.nlm.nih.gov
The objectives of this review are to outline the recent findings related to the morphological
heterogeneity of the biliary epithelium and the heterogeneous pathophysiological responses …

Cholangiocarcinoma in Italy: A national survey on clinical characteristics, diagnostic modalities and treatment. Results from the “Cholangiocarcinoma” committee of …

…, MC Bragazzi, A Benedetti, L Fabris, G Fava… - Digestive and Liver …, 2011 - Elsevier
BACKGROUND: Very few studies assessed cholangiocarcinoma clinical characteristics. AIM:
To evaluate the clinical characteristics of intra-hepatic- and extra-hepatic …

[HTML][HTML] After damage of large bile ducts by gamma-aminobutyric acid, small ducts replenish the biliary tree by amplification of calcium-dependent signaling and de …

…, G Carpino, S Kopriva, M White, G Fava… - The American journal of …, 2010 - Elsevier
Large cholangiocytes secrete bicarbonate in response to secretin and proliferate after bile
duct ligation by activation of cyclic adenosine 3′, 5′-monophosphate signaling. The Ca 2+ -…

Glucagon-like peptide-1 and its receptor agonist exendin-4 modulate cholangiocyte adaptive response to cholestasis

…, C Candelaresi, J Venter, C Rychlicki, G Fava… - Gastroenterology, 2007 - Elsevier
Background & Aims: Cholangiopathies are characterized by progressive dysregulation of
the balance between proliferation and death of cholangiocytes. In the course of cholestasis, …